Determination of cell expansion and surface molecule expression on anti-CD3/28 expanded CD4+ T cells

Scand J Immunol. 2019 Nov;90(5):e12808. doi: 10.1111/sji.12808. Epub 2019 Aug 22.

Abstract

CD4+ T cell immunotherapy has potential for treatment in HIV-infected patients. A large number of expanded CD4+ T cells and confirmation of functional-related phenotypes are required for ensuring the successful outcomes of treatment. Freshly isolated CD4+ T cells from healthy donors were activated with anti-CD3/28-coated magnetic beads at different bead-to-cell ratios and cultured in the absence and presence of IL-2 supplementation for 3 weeks. Fold expansion, cell viability, growth kinetic and lymphocyte subset identities were determined. Data demonstrated that a 1:1 bead-to-cell ratio rendered the highest expansion of 1044-fold with 88% viability and 99.5% purity followed by the 2:1 and 0.5:1 ratios. No significant difference in proliferation and phenotypes was found between non-IL-2 and IL-2 supplementation groups. Several specific surface molecule expressions of the expanded cells including chemokine receptors, adhesion molecules, co-stimulatory molecules, activation molecules, maturation markers, cytokine receptors and other molecules were altered when compared to the unexpanded cells. This optimized expansion protocol using the 1:1 bead-to-cell ratio of anti-CD3/28-coated magnetic beads and culture condition without IL-2 supplementation provided the satisfactory yield with good reproducibility. Specific surface molecule expressions of the expanded cells presented potential roles in proliferation, differentiation, homeostasis, apoptosis and organ homing.

Keywords: CD4+ T lymphocytes; cell expansion; cell surface molecules.

MeSH terms

  • Adult
  • CD28 Antigens / immunology*
  • CD3 Complex / immunology*
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / transplantation*
  • Cell Proliferation
  • Cells, Cultured
  • Coated Materials, Biocompatible
  • HIV Infections / therapy*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Interleukin-2 / immunology
  • Lymphocyte Activation / immunology
  • Magnetite Nanoparticles / therapeutic use*
  • Treatment Outcome

Substances

  • CD28 Antigens
  • CD3 Complex
  • Coated Materials, Biocompatible
  • IL2 protein, human
  • Interleukin-2
  • Magnetite Nanoparticles